AGIO Hits 52-Week Low Amid Trial Setbacks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 Nov 25
Source: SeekingAlpha
Shares of Agios Pharmaceuticals (AGIO.O) plummeted approximately 45% in premarket trading today, marking a new 52-week low for the stock. The significant decline follows mixed results from the late-stage RISE UP trial of mitapivat for sickle cell disease, where the primary endpoint for hemoglobin response was met, but the treatment failed to demonstrate a meaningful reduction in pain crises. Furthermore, serious adverse events were reported in both the treatment and placebo groups, raising concerns among investors. Looking ahead, Agios plans to engage with the U.S. FDA in early 2026 to discuss a marketing application for mitapivat, while also aiming to streamline expenses to facilitate the potential launch of Pyrukynd for thalassemia.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGIO is 36.38 USD with a low forecast of 25.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 28.310
Low
25.00
Averages
36.38
High
62.00
Current: 28.310
Low
25.00
Averages
36.38
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
